PSA Screening Among Elderly Men With Limited Life Expectancies | Cancer Biomarkers | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006.  CA Cancer J Clin. 2006;56:11-2516449183Google ScholarCrossref
2.
American Urological Association.  Prostate-specific antigen (PSA) best practice policy.  Oncology. 2000;14:277-27810736812Google Scholar
3.
National VA Center for Health Promotion and Disease Prevention.  Proposal for new clinical practice guideline for screening men for prostate cancer September 2004. http://www.oqp.med.va.gov/cpg/Publications/USPSTF/Prostate%20Cancer.doc. Accessed July 28, 2006
4.
Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force.  Ann Intern Med. 2002;137:917-92912458993Google ScholarCrossref
5.
Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making.  JAMA. 2001;285:2750-275611386931Google ScholarCrossref
6.
Welch HG, Albertsen PC, Nease RF.  et al.  Estimating treatment benefits for the elderly: the effect of competing risks.  Ann Intern Med. 1996;124:577-5848597322Google ScholarCrossref
7.
Hoffman RM. Viewpoint: limiting prostate cancer screening.  Ann Intern Med. 2006;144:438-44016549856Google ScholarCrossref
8.
Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?  JAMA. 2003;289:1414-142012636464Google ScholarCrossref
9.
Ross LE, Coates RJ, Breen N.  et al.  Prostate-specific antigen test use reported in the 2000 National Health Interview Survey.  Prev Med. 2004;38:732-74415193893Google ScholarCrossref
10.
Volk RJ, Cass AR. The accuracy of primary care patients' self-reports of prostate-specific antigen testing.  Am J Prev Med. 2002;22:56-5811777680Google ScholarCrossref
11.
Jerant AF, Franks P, Jackson JE, Doescher MP. Age-related disparities in cancer screening: analysis of 2001 Behavioral Risk Factor Surveillance System Data.  Ann Fam Med. 2004;2:481-48715506585Google ScholarCrossref
12.
Lu-Yao G, Stukel TA, Yao S. Prostate-specific antigen screening in elderly men.  J Natl Cancer Inst. 2003;95:1792-179714652241Google ScholarCrossref
13.
United States Department of Veterans Affairs.  VA Information Resource Center data sources by name. http://www.virec.research.va.gov/DataSourcesName/DataNames.htm. Accessed July 28, 2006
14.
Veterans Affairs Information Resource Center.  VIReC Research User Guide: FY2004 VHA Medical SAS Outpatient Datasets. Hines, Ill: Edward J. Hines Jr VA Hospital; 2005
15.
Smith MW, Chow A. Fee basis data: a guide for researchers, December 2005. http://www.herc.research.med.va.gov/files/RPRT_366.pdf. Accessed July 28, 2006
16.
VIReC Research User Guide.  VHA DSS Clinical National Data Extracts FY2000-FY2004, Edward J. Hines, Jr. VA Hospital, Hines, IL: Veterans Affairs Information Resource Center, August 2004 (Revised August 2005). http://www.virec.research.va.gov/References/RUG/RUG-DSS00-04.pdf. Accessed July 28, 2006
17.
VA Information Resource Center.  Research findings from the VA Medicare data merge initiative, report to the under secretary for health, September 2003. http://www.virec.research.va.gov/DataSourcesName/VA-MedicareData/USHreport.pdf. Accessed July 28, 2006
18.
Shen Y, Hendricks A, Zhang S, Kazis LE. VHA enrollees' health care coverage and use of care.  Med Care Res Rev. 2003;60:253-26712800686Google ScholarCrossref
19.
Freeman JL, Klabunde CN, Schussler N.  et al.  Measuring breast, colorectal, and prostate cancer screening with Medicare claims data.  Med Care. 2002;40:(8 suppl)  IV-36-IV-4212187166Google ScholarCrossref
20.
 Data verification report for DSS data warehouse, DSS program office database development section, November 2003. http://vaww.dss.med.va.gov/nationalrptg/nr_extracts.asp. Accessed July 28, 2006
21.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;40:373-3833558716Google ScholarCrossref
22.
SEER-Medicare Program.  SAS macro for Charlson Comorbidity Index. http://healthservices.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt. Accessed July 28, 2006
23.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.  J Clin Epidemiol. 1992;45:613-6191607900Google ScholarCrossref
24.
Fowler JE, Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy.  J Urol. 1996;156:1714-17188863577Google ScholarCrossref
25.
US Census Bureau.  Census regions and divisions of the United States/prepared by the US Census Bureau. http://www.census.gov/geo/www/us_regdiv.pdf. Accessed July 28, 2006
26.
US Census Bureau.  Census 2000 summary file 3–United States/prepared by the US Census Bureau, 2002. http://www2.census.gov/census_2000/datasets/Summary_File_3/0_National/. Accessed July 28, 2006
27.
US Department of Health and Human Services Centers for Disease Control and Prevention.  United States life tables, 2003, volume 54, no. 14. http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf. Accessed July 28, 2006
28.
Shryock HS, Siegel JS.  et al.  The Methods and Materials of Demography. New York, NY: Academic Press Inc; 1976
29.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index.  J Clin Epidemiol. 1994;47:1245-12517722560Google ScholarCrossref
30.
de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods.  J Clin Epidemiol. 2003;56:221-22912725876Google ScholarCrossref
31.
Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening.  Ann Intern Med. 2006;144:441-44316549857Google ScholarCrossref
32.
Draisma G, Otto SJ, van der Cruijsen IW.  et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer.  J Natl Cancer Inst. 2003;95:868-87812813170Google ScholarCrossref
33.
Jacobsen SJ, Bergstralh EJ, Guess HA.  et al.  Predictive properties of serum prostate-specific antigen testing in a community-based setting.  Arch Intern Med. 1996;156:2462-24688944739Google ScholarCrossref
34.
McNaughton-Collins M, Fowler FJ, Caubet J.  et al.  Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result.  Am J Med. 2004;117:719-72515541320Google ScholarCrossref
35.
Barry MJ. PSA screening for prostate cancer: the current controversy—a viewpoint.  Ann Oncol. 1998;9:1279-12829932155Google ScholarCrossref
36.
Stamey TA, Caldwell M, McNeal JE.  et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?  J Urol. 2004;172:1297-130115371827Google ScholarCrossref
37.
Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer.  J Urol. 1990;143:742-7462313798Google Scholar
38.
Stanford JL, Feng Z, Hamilton AS.  et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer.  JAMA. 2000;283:354-36010647798Google ScholarCrossref
39.
Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J. Racial differences in screening for prostate cancer in the elderly.  Arch Intern Med. 2004;164:1858-186415451760Google ScholarCrossref
40.
Woloshin S, Schwartz LM. The US Postal Service and cancer screening: stamps of approval?  N Engl J Med. 1999;340:884-88710080855Google ScholarCrossref
41.
Krahn MD, Bremner KE, Asaria J.  et al.  The ten-year rule revisted: accuracy of clinicians' estmates of life expectancy in patients with localized prostate cancer.  Urology. 2002;60:258-26312137823Google ScholarCrossref
42.
Voss JD, Schectman JM. Prostate cancer screening practices and beliefs: a longitudinal physician survey.  J Gen Intern Med. 2001;16:831-83711903762Google ScholarCrossref
43.
Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure.  JAMA. 2004;291:2466-247015161897Google ScholarCrossref
44.
VA Office of Quality and Performance.  FY 2003 VHA performance measurement system technical manual 2003. http://vaww.oqp.med.va.gov/oqp_services/performance_measurement/tech_man.asp. Accessed July 28, 2006
45.
Kizer KW, Demakis JG, Feussner JR. Reinventing VA health care.  Med Care. 2000;38:(suppl 1)  I7-I1610843266Google ScholarCrossref
46.
Wolf AM, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening.  Arch Intern Med. 1996;156:1333-13368651843Google ScholarCrossref
47.
Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up.  Ann Fam Med. 2003;1:22-2815043176Google ScholarCrossref
Original Contribution
November 15, 2006

PSA Screening Among Elderly Men With Limited Life Expectancies

Author Affiliations
 

Author Affiliations: Division of Geriatrics, San Francisco VA Medical Center and the Division of Geriatrics, University of California, San Francisco (Dr Walter and Ms Lindquist); Research Enhancement Award Program to Improve Care for Older Veterans, San Francisco VA Medical Center (Mr Bertenthal); and Department of Urology, University of California, San Francisco (Dr Konety).

JAMA. 2006;296(19):2336-2342. doi:10.1001/jama.296.19.2336
Abstract

Context Most guidelines do not recommend prostate-specific antigen (PSA) screening in elderly men who have limited life expectancies because the known harms of screening outweigh potential benefits. However, there are no large-scale studies of actual PSA screening practices in elderly men, according to life expectancy.

Objective To characterize the extent of PSA screening among elderly men, including those with limited life expectancies.

Design, Setting, and Participants Cohort study of 597 642 male veterans aged 70 years and older who were seen at 104 US Department of Veterans Affairs facilities during both 2002 and 2003, without a history of prostate cancer, elevated PSA, or prostate cancer symptoms. Charlson comorbidity scores were used to stratify men into 3 groups ranging from best health (score = 0) to worst health (score ≥ 4).

Main Outcome Measure Receipt of PSA testing during 2003 was based on US Department of Veterans Affairs data and Medicare claims.

Results In 2003, 56% of elderly men had a PSA test performed. Although PSA screening rates decreased with advancing age, within each 5-year age group the percentage of men who underwent a PSA test did not substantially decline with worsening health. For example, among men aged 85 years and older, 34% in best health had a PSA test compared with 36% in worst health. In multivariate analyses, many nonclinical factors, such as marital status and region of the country, had a greater effect on PSA screening than health, and screening rates exceeded 60% for some subgroups of men in worst health.

Conclusions Prostate-specific antigen screening rates among elderly veterans with limited life expectancies should be much lower than current practice given the known harms of screening. More attention to prognosis is needed when making screening PSA recommendations to elderly men.

×